SINGLE-DOMAIN ANTIBODY FOR NEUTRALIZING VIRUSES AND ITS MODIFICATION, AND A METHOD FOR THEIR USE FOR EMERGENCY PREVENTION OF DISEASES CAUSED BY INFLUENZA A VIRUS Russian patent published in 2022 - IPC C07K16/10 C12N15/13 

FIELD: biotechnology.

SUBSTANCE: group of inventions relates to the field of biotechnology, immunology and microbiology and concerns the neutralization of the influenza A virus. A single-domain antibody has been proposed that specifically binds to the stem hemagglutinin domain of the influenza A virus and has the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2. An oligomerized single-domain antibody has also been proposed, which specifically binds to the stem hemagglutinin domain of the influenza A virus, containing a single-domain antibody as a monomeric block and having the final amino acid sequence SEQ ID NO: 3 or SEQ ID NO: 4. A recombinant antibody has also been created, which is a single-domain antibody fused with the Fc fragment of human immunoglobulin G2, which binds to the stem hemagglutinin domain of the influenza A virus and has the final amino acid sequence SEQ ID NO: 5 or SEQ ID NO: 6. A method for emergency prevention of the disease caused by the influenza A virus is also disclosed, which consists in introducing an effective amount of the created antibody into the mammalian body.

EFFECT: group of inventions makes it possible to create single-domain antibodies and their modifications that effectively bind the stem hemagglutinin domain of the influenza A virus, neutralize the influenza A virus and can be used for emergency prevention of diseases caused by the influenza A virus, have less pronounced affinity for the human Fc receptor compared to IgG1.

4 cl, 11 dwg, 3 tbl, 14 ex